Jonathan Zalevsky

Insider Reports History

Entity
Individual
Location
455 Mission Bay Boulevard South, C/O Nektar Therapeutics, San Francisco, California
Signature
Mark A. Wilson, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Jonathan Zalevsky:

Stock Role Class Num Shares Value Price $ Report Date Ownership
NEKTAR THERAPEUTICS Chief R&D Officer Common Stock 258K $451K $1.75 May 17, 2024 Direct
NEKTAR THERAPEUTICS Chief R&D Officer Stock Option 250K Dec 13, 2023 Direct

Insider Reports Filed by Jonathan Zalevsky

Symbol Company Period Transactions Value $ Form Type Date Filed Role
NKTR NEKTAR THERAPEUTICS May 17, 2024 1 -$12.9K 4 May 20, 2024 Chief R&D Officer
NKTR NEKTAR THERAPEUTICS Feb 20, 2024 1 -$6.13K 4 Feb 22, 2024 Chief R&D Officer
NKTR NEKTAR THERAPEUTICS Dec 13, 2023 1 $0 4 Dec 15, 2023 Chief R&D Officer
NKTR NEKTAR THERAPEUTICS Nov 17, 2023 1 -$4.73K 4 Nov 20, 2023 Chief R&D Officer
NKTR NEKTAR THERAPEUTICS Aug 16, 2023 1 -$7.57K 4 Aug 17, 2023 Chief R&D Officer
NKTR NEKTAR THERAPEUTICS May 16, 2023 1 -$7.05K 4 May 17, 2023 Chief R&D Officer
NKTR NEKTAR THERAPEUTICS Feb 16, 2023 1 -$31.5K 4 Feb 17, 2023 Chief R&D Officer
NKTR NEKTAR THERAPEUTICS Nov 16, 2022 1 -$48.1K 4 Nov 18, 2022 Chief R&D Officer
NKTR NEKTAR THERAPEUTICS Aug 18, 2022 1 -$343K 4 Aug 19, 2022 Chief R&D Officer
NKTR NEKTAR THERAPEUTICS Aug 15, 2022 3 -$50.3K 4 Aug 17, 2022 Chief R&D Officer
NKTR NEKTAR THERAPEUTICS May 15, 2022 2 -$85.6K 4 May 17, 2022 Chief R&D Officer
NKTR NEKTAR THERAPEUTICS Feb 16, 2022 1 -$119K 4 Feb 18, 2022 Chief R&D Officer
NKTR NEKTAR THERAPEUTICS Dec 16, 2021 2 $0 4 Dec 20, 2021 Chief R&D Officer
NKTR NEKTAR THERAPEUTICS Nov 15, 2021 2 -$275K 4 Nov 17, 2021 Chief R&D Officer
NKTR NEKTAR THERAPEUTICS Oct 12, 2021 1 $0 4 Oct 14, 2021 Chief R&D Officer
NKTR NEKTAR THERAPEUTICS Aug 16, 2021 1 -$106K 4 Aug 18, 2021 Chief R&D Officer
NKTR NEKTAR THERAPEUTICS May 17, 2021 1 -$569K 4 May 19, 2021 Chief R&D Officer